Registro:

Referencias:

• Greenlee, R.T., Murray, T., Bolden, S., Wingo, P.A., Cancer statistics, 2000 (2000) CA Cancer J. Clin., 50, p. 7
• Timmerman, J.M., Levy, R., Dendritic cell vaccines for cancer immunotherapy (1999) Annu. Rev. Med., 50, p. 507
• Fong, L., Engleman, E.G., Dendritic cells in cancer immunotherapy (2000) Annu. Rev. Immunol., 18, p. 245
• Schuler, G., Schuler-Thurner, B., Steinman, R.M., The use of dendritic cells in cancer immunotherapy (2003) Curr. Opin. Immunol., 15, p. 138
• Banchereau, J., Schuler-Thurner, B., Palucka, A.K., Schuler, G., Dendritic cells as vectors for therapy (2001) Cell, 106, p. 271
• Banchereau, J., Steinman, R.M., Dendritic cells and the control of immunity (1998) Nature, 392, p. 245
• Reid, S.D., Penna, G., Adorini, L., The control of T cell responses by dendritic cell subsets (2000) Curr. Opin. Immunol., 12, p. 114
• Lanzavecchia, A., Sallusto, F., Regulation of T cell immunity by dendritic cells (2001) Cell, 106, p. 263
• Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C., Amigorena, S., Antigen presentation and T cell stimulation by dendritic cells (2002) Annu. Rev. Immunol., 20, p. 621
• Dhodapkar, M., Steinman, R.M., Sapp, M., Desai, H., Fossella, C., Krasovsky, J., Donahoe, S.M., Nixon, D.F., Rapid generation of broad T-cell immunity in humans after single injection of mature dendritic cells (1999) J. Clin. Invest., 104, p. 173
• Dhodapkar, M.V., Krasovsky, J., Steinman, R.M., Bhardwaj, N., Mature dendritic cells boost functionally superior T cells in humans without foreign helper epitopes (2000) J. Clin. Invest., 105, pp. R9
• Thurner, B., Haendle, I., Roder, C., Dieckmann, D., Keikavoussi, P., Jonuleit, H., Bender, A., Von Den Driesch, P., Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma (1999) J. Exp. Med., 190, p. 1669
• Banchereau, J., Palucka, A.K., Dhodapkar, M., Burkeholder, S., Taquet, N., Rolland, A., Taquet, S., Bhardwaj, N., Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine (2001) Cancer Res., 61, p. 6451
• Schuler-Thurner, B., Schultz, E.S., Berger, T.G., Weinlich, G., Ebner, S., Woerl, P., Bender, A., Romani, N., Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells (2002) J. Exp. Med., 195, p. 1279
• Schuler-Thurner, B., Dieckmann, D., Keikavoussi, P., Bender, A., Maczek, C., Jonuleit, H., Roder, C., Dunbar, R., Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A. 2.1+ melanoma patients by mature monocyte-derived dendritic cells (2000) J. Immunol., 165, p. 3492
• Nestle, F.O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., Schadendorf, D., Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells (1998) Nat. Med., 4, p. 328
• Zitvogel, L., Mayordomo, J.I., Tjandrawan, T., DeLeo, A.B., Clarke, M.R., Lotze, M.T., Storkus, W.J., Therapy of murine tumors with tumor peptide pulsed dendritic cells: Dependence on T-cells, B7 costimulation, and Th1-associated cytokines (1996) J. Exp. Med., 183, p. 87
• Boczkowski, D., Nair, S.K., Snyder, D., Gilboa, E., Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo (1996) J. Exp. Med., 184, p. 465
• Nair, S.K., Heiser, A., Boczkowski, D., Majumdar, A., Naoe, M., Lebkowski, J.S., Vieweg, J., Gilboa, E., Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells (2000) Nat. Med., 6, p. 1011
• Fields, R.C., Shimizu, K., Mule, J.J., Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo (1998) Proc. Natl. Acad. Sci. USA, 95, p. 9482
• Wolfers, J., Lozier, A., Raposo, G., Regnault, A., Thery, C., Masurier, C., Flament, C., Tursz, T., Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming (2001) Nat. Med., 7, p. 297
• Berard, F., Blanco, P., Davoust, J., Neidhart-Berard, E.-M., Nouri-Shirazi, M., Taquet, N., Rimoldi, D., Palucka, A.K., Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells (2000) J. Exp. Med., 192, p. 1535
• Shaif-Muthana, M., McIntyre, C., Sisley, K., Rennie, I., Murray, A., Dead or alive: Immunogenicity of human melanoma cells when presented by dendritic cells (2000) Cancer Res., 60, p. 6441
• Hoffmann, T.K., Meidenbauer, N., Dworacki, G., Kanaya, H., Whiteside, T.L., Generation of tumor-specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells (2000) Cancer Res., 60, p. 3542
• Paczesny, S., Beranger, S., Salzmann, J.L., Klatzmann, D., Colombo, B.M., Protection of mice against leukemia after vaccination with bone marrow-derived dendritic cells loaded with apoptotic leukemia cells (2001) Cancer Res., 61, p. 2386
• Ronchetti, A., Rovere, P., Iezzi, G., Galati, G., Heltai, S., Protti, M.P., Garancini, M.P., Bellone, M., Immunogenicity of apoptotic cells in vivo: Role of antigen load, antigen-presenting cells, and cytokines (1999) J. Immunol., 163, p. 130
• Albert, M.L., Sauter, B., Bhardwaj, N., Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs (1998) Nature, 392, p. 86
• Inaba, K., Turley, S., Yamaide, F., Iyoda, T., Mahnke, K., Inaba, M., Pack, M., Sheff, D., Efficient presentation of phagocytosed cellular fragments on the MHC class II products of dendritic cells (1998) J. Exp. Med., 188, p. 2163
• Dhodapkar, K.M., Krasovsky, J., Williamson, B., Dhodapkar, M.V., Anti-tumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells (2002) J. Exp. Med., 195, p. 125
• Dhodapkar, M.V., Krasovsky, J., Olson, K., T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells (2002) Proc. Natl. Acad. Sci. USA, 99, p. 13009
• Wang, H.Y., Fu, T., Wang, G., Zeng, G., Perry-Lalley, D.M., Yang, J.C., Restifo, N.P., Wang, R.F., Induction of CD4+ T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells (2002) J. Clin. Invest., 109, p. 1463
• Shibagaki, N., Udey, M.C., Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma (2003) Eur. J. Immunol., 33, p. 850
• Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., Levitsky, D., The central role of CD4+ T cells in the antitumor immune response (1998) J. Exp. Med., 188, p. 2357
• Fidler, I.J., Nicolson, G.L., Tumor cell and host properties affecting the implantation and survival of blood-borne metastatic variants of B16 melanoma (1978) Isr. J. Med. Sci., 14, p. 38
• Lutz, M.B., Kukutsch, N., Ogilvie, A.L.J., RoBner, S., Koch, F., Romani, N., Schuler, G., An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow (1999) J. Immunol. Methods, 223, p. 77
• Josien, R., Hi, H.-L., Ingulli, E., Sarma, S., Wong, B.R., Vologodskaia, M., Steinman, R.M., Choi, Y., TRANCE, a tumor necrosis family member, enhances the longevity and adjuvant properties of dendritic cells in vivo (2000) J. Exp. Med., 191, p. 495
• Fernandez, N.C., Lozier, A., Flament, C., Ricciardi-Castagnoli, P., Bellet, D., Suter, M., Perricaudet, M., Zitvogel, L., Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo (1999) Nat. Med., 5, p. 405
• Zitvogel, L., Dendritic and natural killer cells cooperate in the control/switch of innate immunity (2002) J. Exp. Med., 195, pp. F9
• Ferlazzo, G., Tsang, M.L., Moretta, L., Melioli, G., Steinman, R.M., Munz, C., Human dendritic cells activate resting NK cells and are recognized via the NKp30 receptor by activated NK cells (2002) J. Exp. Med., 195, p. 343
• Stober, D., Jomantaite, I., Schirmbeck, R., Reimann, J., NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo (2003) J. Immunol., 170, p. 2540
• Schnell, S., Young, J.W., Houghton, A.N., Sadelain, M., Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: Implications for the clinical use of dendritic cells (2000) J. Immunol., 164, p. 1243
• Wang, R.-F., Appella, E., Kawakami, Y., Kang, X., Rosenberg, S.A., Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes (1996) J. Exp. Med., 184, p. 2207
• Parkhurst, M.R., Fitzgerald, E.B., Southwood, S., Sette, A., Rosenberg, S.A., Kawakami, Y., Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2) (1998) Cancer Res., 58, p. 4895
• Bloom, M.B., Perry-Lalley, D., Robbins, P.F., Li, Y., El-Gamil, M., Rosenberg, S.A., Yang, J.C., Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma (1997) J. Exp. Med., 185, p. 453
• Bowne, W.B., Srinivasan, R., Wolchok, J.D., Hawkins, W.G., Blachere, N.E., Dyall, R., Lewis, J.J., Houghton, A.N., Coupling and uncoupling of tumor immunity and autoimmunity (1999) J. Exp. Med., 190, p. 1717
• Kotera, Y., Shimizu, K., Mule, J.J., Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization (2001) Cancer Res., 61, p. 8105
• Chen, Z., Moyana, T., Saxena, A., Warrington, R., Jia, Z., Xiang, J., Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells (2001) Int. J. Cancer, 93, p. 539
• Sauter, B., Albert, M.L., Francisco, L., Larsson, M., Somersan, S., Bhardwaj, N., Consequences of cell death. Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells (2000) J. Exp. Med., 191, p. 423
• Rovere, P., Vallinoto, C., Bondanza, A., Crosti, M.C., Rescigno, M., Ricciardi-Castagnoli, P., Rugarli, C., Manfredi, A.A., Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function (1998) J. Immunol., 161, p. 4467
• Ossendorp, F., Mengede, E., Camps, M., Filius, R., Melief, C.J.M., Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors (1998) J. Exp. Med., 187, p. 693
• Mumberg, D., Monach, P.A., Wanderling, S., Philip, M., Toledano, A.Y., Schreiber, R.D., Schreiber, H., CD4+ T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ (1999) Proc. Natl. Acad. Sci. USA, 96, p. 8633
• Marzo, A.L., Kinnear, B.F., Lake, R.A., Frelinger, J.J., Collins, E.J., Robinson, B.W., Scott, B., Tumor-specific CD4+ T cells have a major " post-licensing" role in CTL mediated anti-tumor immunity (2000) J. Immunol., 165, p. 6047
• Stohlman, S.A., Bergmann, C.C., Lin, M.T., Cua, D.J., Hinton, D.R., CTL effector function within the central nervous system requires CD4 + T cells (1998) J. Immunol., 160, p. 2896
• Bohm, W., Thoma, S., Leithauser, F., Moller, P., Schirmbeck, R., Reimann, J., T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas (1998) Immunol., 161, p. 897
• Weber, J.S., Rosenberg, S.A., Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro (1988) Cancer Res., 48, p. 5818
• Kaplan, D.H., Shankaran, V., Dighe, A.S., Stockert, E., Aguet, M., Old, L.J., Schreiber, R.D., Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice (1998) Proc. Natl. Acad. Sci. USA, 95, p. 7556
• Rammensee, H., Bachmann, J., Emmerich, N.P., Bachor, O.A., Stevanovic, S., SYFPEITHI: Database for MHC ligands and peptide motifs (1999) Immunogenetics, 50, p. 213
• Brown, J.H., Jardetzky, T.S., Gorga, J.C., Stern, L.J., Urban, R.G., Strominger, J.L., Wiley, D.C., Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1 (1993) Nature, 364, p. 33
• Fremont, D.H., Hendrickson, W.A., Marrack, P., Kappler, J., Structures of an MHC class II molecule with covalently bound single peptides (1996) Science, 272, p. 1001
• Reinherz, E.L., Tan, K., Tang, L., Kern, P., Liu, J., Xiong, Y., Hussey, R.E., Zhang, R., The crystal structure of a T cell receptor in complex with peptide and MHC class II (1999) Science, 286, p. 1913
• Shimizu, K., Thomas, E.K., Giedlin, M., Mule, J.J., Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein (2001) Cancer Res., 61, p. 2618
• Strome, S.E., Voss, S., Wilcox, R., Wakefield, T.L., Tamada, K., Flies, D., Chapoval, A., Padley, D., Strategies for antigen loading of dendritic cells to enhance the antitumor immune response (2002) Cancer Res., 62, p. 1884
• Schnurr, M., Scholz, C., Rothenfusser, S., Galambos, P., Dauer, M., Robe, J., Endres, S., Eigler, A., Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and γδ T cells (2002) Cancer Res., 62, p. 2347

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------